Drug Makers Continue 340B Pharmacy Restrictions Despite HHS Opinion

By Michelle M. Stein / January 8, 2021 at 4:02 PM

Sanofi, AstraZeneca and Novartis officials told Inside Health Policy their companies continue to restrict 340B discounts available through contract pharmacies, and Eli Lilly reportedly is continuing its restrictions as well, despite a recent HHS General Counsel advisory opinion asking the drug makers to scrap their policies and restore the discounts.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.